Cancer Genetics: A Primer for Surgeons

Surgical Clinics of North America

Volumn 88, Issue 4, 2008, Pages 681-704

  Benson, John R ^a,b   Liau, Siong Seng ^a,c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b SELWYN COLLEGE   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE KINASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; CANCER GENETICS; CANCER STEM CELL; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME TRANSLOCATION; EPIGENETICS; FAMILIAL CANCER; GENE AMPLIFICATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MISSENSE MUTATION; ONCOGENE C MYB; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE MYC; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SPONTANEOUS MUTATION; SURGEON; TUMOR GENE; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 47849091206     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.04.011     Document Type: Review

References (63)

1. Frank L.M., and Teich N.M. Introduction to the cellular and molecular biology of cancer (1995), Oxford University Press, New York
2. Benson J.R., Baum M., and Colletta A.A. Role of TGF beta in the anti-estrogen response/resistance of human breast cancer. J Mammary Gland Biol Neoplasia 1 4 (1996) 381-389
3. Bishop J.M., and Weinberg R.A. Molecular oncology (1996), Scientific American Inc.,, New York
4. Bodmer W.F. Inherited susceptibility to cancer. In: Frank L.M., and Teich N.M. (Eds). Introduction to the cellular and molecular biology of cancer. 2nd edition (1995), Oxford University Press, New York 98-124
5. Knudson Jr. A.G. Genetics of human cancer. Annu Rev Genet 20 (1986) 231-251
6. Knudson Jr. A.G. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45 4 (1985) 1437-1443
7. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 5 (1990) 759-767
8. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
9. Stewart S.A., and Weinberg R.A. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 22 (2006) 531-557
10. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N Engl J Med 355 12 (2006) 1253-1261
11. Greaves M. Cancer causation: the Darwinian downside of past success?. Lancet Oncol 3 4 (2002) 244-251
12. Dalerba P., Cho R.W., and Clarke M.F. Cancer stem cells: models and concepts. Annu Rev Med 58 (2007) 267-284
13. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 6859 (2001) 105-111
14. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 5405 (1973) 290-293
15. Brodeur G.M. Molecular pathology of human neuroblastomas. Semin Diagn Pathol 11 2 (1994) 118-125
16. Catteau A., and Morris J.R. BRCA1 methylation: a significant role in tumour development?. Semin Cancer Biol 12 5 (2002) 359-371
17. Kinzler K.W., and Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386 6627 (1997) 761-763
18. Sharan S.K., Morimatsu M., Albrecht U., et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386 6627 (1997) 804-810
19. Weaver B.A., and Cleveland D.W. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67 21 (2007) 10103-10105
20. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 7015 (2004) 316-323
21. Kops G.J., Weaver B.A., and Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5 10 (2005) 773-785
22. Lobrich M., and Jeggo P.A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7 11 (2007) 861-869
23. Mountzios G., Terpos E., and Dimopoulos M.A. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34 (2008) 175-182
24. Hahn W.C. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 21 10 (2003) 2034-2043
25. Artandi S.E., and Attardi L.D. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 331 3 (2005) 881-890
26. Saldivar J.S., Wu X., Follen M., et al. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 107 1 Suppl 1 (2007) S56-S71
27. Leibeling D., Laspe P., and Emmert S. Nucleotide excision repair and cancer. J Mol Histol 37 5-7 (2006) 225-238
28. Soreide K., Janssen E.A., Soiland H., et al. Microsatellite instability in colorectal cancer. Br J Surg 93 4 (2006) 395-406
29. Vasen H.F. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther 26 Suppl 2 (2007) 113-126
30. Li G.M. Mechanisms and functions of DNA mismatch repair. Cell Res 18 1 (2008) 85-98
31. Fishel R., Lescoe M.K., Rao M.R., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 5 (1993) 1027-1038
32. Butel J.S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21 3 (2000) 405-426
33. Rous P. Viruses and tumour causation. An appraisal of present knowledge. Nature 207 996 (1965) 457-463
34. Toren A., Ben-Bassat I., and Rechavi G. Infectious agents and environmental factors in lymphoid malignancies. Blood Rev 10 2 (1996) 89-94
35. De Larco J.E., and Todaro G.J. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A 75 8 (1978) 4001-4005
36. Turner C.E., and Burridge K. Transmembrane molecular assemblies in cell-extracellular matrix interactions. Curr Opin Cell Biol 3 5 (1991) 849-853
37. Zwick E., Bange J., and Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8 3 (2001) 161-173
38. Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol 8 2 (2006) 77-82
39. Cruz J.J., Ocana A., Del Barco E., et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 18 3 (2007) 421-430
40. Lo H.W., Hsu S.C., and Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95 3 (2006) 211-218
41. Baselga J., and Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl 1 (2001) S35-S41
42. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5 5 (2005) 367-375
43. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 3 6 (2003) 459-465
44. Mirza A.M., Gysin S., Malek N., et al. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 24 24 (2004) 10868-10881
45. Nesbit C.E., Tersak J.M., and Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 18 19 (1999) 3004-3016
46. Vogel F. Genetics of retinoblastoma. Hum Genet 52 1 (1979) 1-54
47. Knudson A.G. Cancer genetics. Am J Med Genet 111 1 (2002) 96-102
48. Ford D., and Easton D.F. The genetics of breast and ovarian cancer. Br J Cancer 72 4 (1995) 805-812
49. Merajver S.D., Pham T.M., Caduff R.F., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9 4 (1995) 439-443
50. Harbour J.W., and Dean D.C. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2 4 (2000) E65-E67
51. Blackburn A.C., and Jerry D.J. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?. Breast Cancer Res 4 3 (2002) 101-111
52. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 4985 (1990) 1233-1238
53. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 2 (2002) 103-112
54. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 10 (2001) 731-737
55. Clevers H. Wnt breakers in colon cancer. Cancer Cell 5 1 (2004) 5-6
56. Benson J.R. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 5 4 (2004) 229-239
57. Viktorsson K., Lewensohn R., and Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 94 (2005) 143-196
58. Sanchez-Beato M., Sanchez-Aguilera A., and Piris M.A. Cell cycle deregulation in B-cell lymphomas. Blood 101 4 (2003) 1220-1235
59. Miremadi A., Oestergaard M.Z., Pharoah P.D., et al. Cancer genetics of epigenetic genes. Hum Mol Genet 16 Spec No 1 (2007) R28-R49
60. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36 18 (2000) 2294-2300
61. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1 (2007) R50-R59
62. Pierce G.B., and Speers W.C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48 8 (1988) 1996-2004
63. Schipper H., Goh C.R., and Wang T.L. Shifting the cancer paradigm: must we kill to cure?. J Clin Oncol 13 4 (1995) 801-807